A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
CONCLUSIONS: The pulsed EHC Pop PK model characterized the teriflunomide PK processes well in both healthy subjects and patients. Body weight, sex, and ABCG2 34G>A genotype were identified to significantly affect PK characteristics. The developed EHC Pop PK model exhibited the ability to predict PK profiles of teriflunomide in patients after long-term dosing and could be utilized to support phase II trial design.
PMID: 31154006 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Yao X, Wu Y, Jiang J, Chen X, Liu D, Hu P Tags: Eur J Pharm Sci Source Type: research
More News: Arthritis | Drugs & Pharmacology | Lupus | Rheumatoid Arthritis | Rheumatology | Sodium | Study